Li J M, Hou J, Li L, Wang Y
Department of Pathology, Sichuan Cancer Hospital, Chengdu, China
Department of Pathology, Sichuan Cancer Hospital, Chengdu, China.
Genet Mol Res. 2015 Apr 27;14(2):3889-96. doi: 10.4238/2015.April.27.3.
The objectives of this study were to detect immunohistochemical subtypes of diffuse large B-cell lymphoma (DLBCL) of the head and neck, to compare the Hans, Choi, and Tally algorithms and to examine the significance of protein expression in these algorithms. This study included 103 DLBCL patients at Sichuan Cancer Hospital between May 2010 and October 2012. Immunohistochemistry was per-formed for CD10, B-cell lymphoma 6 protein (Bcl-6), mutated melanoma-associated antigen 1 (MUM1), germinal center B-cell-expressed transcript 1 (GCET1), forkhead box protein P1 (FOXP1), and LIM do-main only 2 (LMO2). Subtypes were determined according to the Hans, Choi, and Tally algorithms. Positive staining for CD10 was detected in 16 patients (15.53%), for Bcl-6 in 68 patients (66.02%), for MUM1 in 69 patients (66.99%), for GCET1 in 21 patients (20.39%), for FOXP1 in 75 patients (72.82%), and for LMO2 in 50 patients (48.54%). The Hans algorithm identified 26 patients (25.2%) with the germinal center B-cell (GCB) subtype and 77 (74.8%) with the activated B-cell (ABC) subtype. In the Choi algorithm, 25 patients (24.3%) were identified with the GCB subtype and 78 (75.7%) with the ABC subtype. In the Tally algorithm, 20 patients (19.4%) had the GCB subtype and 83 (80.6%) had the ABC subtype. Expression of CD10, MUM1, GCET1, FOXP1, and LMO2 correlated with algorithm (P < 0.05); however, Bcl-6 did not correlate with the Hans and Choi algorithms. DLBCL of the head and neck is most commonly the ABC subtype, not GCB. The Hans, Choi, and Tally algorithms were not significantly different.
本研究的目的是检测头颈部弥漫性大B细胞淋巴瘤(DLBCL)的免疫组织化学亚型,比较汉斯(Hans)、崔氏(Choi)和塔利(Tally)算法,并探讨这些算法中蛋白表达的意义。本研究纳入了2010年5月至2012年10月期间在四川省肿瘤医院就诊的103例DLBCL患者。对CD10、B细胞淋巴瘤6蛋白(Bcl-6)、突变型黑色素瘤相关抗原1(MUM1)、生发中心B细胞表达转录本1(GCET1)、叉头框蛋白P1(FOXP1)和仅含LIM结构域2(LMO2)进行免疫组织化学检测。根据汉斯、崔氏和塔利算法确定亚型。16例患者(15.53%)CD10染色阳性,68例患者(66.02%)Bcl-6染色阳性,69例患者(66.99%)MUM1染色阳性,21例患者(20.39%)GCET1染色阳性,75例患者(72.82%)FOXP1染色阳性,50例患者(48.54%)LMO2染色阳性。汉斯算法确定26例患者(25.2%)为生发中心B细胞(GCB)亚型,77例患者(74.8%)为活化B细胞(ABC)亚型。在崔氏算法中,25例患者(24.3%)为GCB亚型,78例患者(75.7%)为ABC亚型。在塔利算法中,20例患者(19.4%)为GCB亚型,83例患者(80.6%)为ABC亚型。CD10、MUM1、GCET1、FOXP1和LMO2的表达与算法相关(P<0.05);然而,Bcl-6与汉斯和崔氏算法无关。头颈部DLBCL最常见的是ABC亚型,而非GCB亚型。汉斯、崔氏和塔利算法无显著差异。